Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 23

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 23
---
continuation of the Company as a going concern. The Company has had no revenues from product sales since inception and incurred a
net loss of $6,069,866 and had negative cash flows of operations totaling $3,045,713 for the nine months ended September 30, 2025,
and a cumulative net loss since inception totaling $32,091,995.

In
management’s opinion, these conditions raise substantial doubt about the Company’s ability to continue as a going concern
for a period of at least twelve months from the date of this report. The Company plans to finance future operations with proceeds from
equity securities, grant awards, and strategic collaborations. However, there is no assurance that the Company will be able to affect
transactions on commercially reasonable terms, if at all.

Components
of Results of Operations

Research
and Development Expenses

Research
and development expense reflects costs to advance our pharmaceutical programs and support product development for our consumer health
initiatives. Key drivers include third-party service agreements to accelerate development and distribution efforts in Asia and program-level
activities such as procurement of clinical trial supplies. We expense research and development expenses as incurred, and certain multi-period
service arrangements are recognized ratably over their terms, which can create period-to-period variability as new agreements commence
or milestones occur.

General
and Administrative Expenses

General
and administrative expense comprises corporate overhead necessary to operate as a public company and to support our dual focus on pharmaceuticals
and premium nutritional supplements. Major components include personnel-related costs, professional fees (legal, accounting, regulatory,
commercialization support), facilities and insurance, and other public-company compliance costs. Fluctuations versus prior periods primarily
reflect changes in staffing, stock-based compensation, external advisory needs, and launch-readiness activities for the consumer health
business.

Interest
Income

Interest
income is generated from cash and cash equivalents, with period-to-period changes driven by average cash balances and prevailing short-term
yields. The timing of capital raises, and operating cash usage can influence both the absolute level of interest income and its variability
across reporting periods. Our policy treats highly liquid investments with original maturities of three months or less as cash equivalents.

Interest
Expense

Interest
expense primarily arises from financing arrangements recorded on our balance sheet (including notes payable), and will vary based on
outstanding principal, effective interest rates, and any amortization of related financing costs. Changes in borrowings or the terms
of such obligations can therefore impact period-over-period compar